Browsing Tag
Cantor
4 posts
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
Sleep apnoea biotech Apnimed (APMD) climbs in Nasdaq debut after upsized offering
Apnimed raised $192M in an upsized Nasdaq IPO to fund oxnimbi's launch, with the FDA's February 28, 2027 decision on the first oral OSA pill now the pivot.
Did Tango Therapeutics Inc. just turn one cancer data shock into a $600m runway?
Find out how Tango Therapeutics Inc.'s $600 million offering could reshape TNGX sentiment, dilution risk, and its oncology runway.
Quantinuum IPO closes at $1.68bn, but QNT trading shows investors want proof beyond quantum hype
Quantinuum raised $1.68bn, but QNT’s early trading asks the real question: can quantum computing turn promise into revenue?